ABCL - AbCellera secures GMP manufacturing facility for therapeutic antibodies in Canada

AbCellera ([[ABCL]] -3.0%) has secured a site in Vancouver, Canada for the construction of a Good Manufacturing Practices ((GMP)) manufacturing facility for the production of therapeutic antibodies.The 130,000-square-foot facility will expand AbCellera’s capabilities in bringing new antibody therapies to clinical trials, supporting Canada’s efforts to respond quickly and effectively to future pandemics and to accelerate programs from a drug target to the IND submission. The new GMP facility will be built on a vacant two-acre site, and the planned building will house laboratory, office, GMP protein biologic manufacturing, and warehouse space.Design efforts are already underway and groundbreaking is scheduled for later this year. The facility is scheduled to be ready for GMP manufacturing in early 2024.The development of the new GMP manufacturing facility is funded in part by a $125.6M grant from the Canadian government.In parallel with the construction of the new facility, AbCellera is also building up an internal

For further details see:

AbCellera secures GMP manufacturing facility for therapeutic antibodies in Canada